CliffBio
small molecule

SKYLA

LEVONORGESTREL

Loss of exclusivitySeptember 2029latest FDA-listed patent expiry
CompanyBayer Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameSKYLA
Active ingredientLEVONORGESTREL
Strength13.5MG
Dosage formSYSTEM
RouteINTRAUTERINE
ModalitySmall molecule
FDA approvalJanuary 2013
Marketing statusRX

Listed patents

PatentExpiresType
10561524September 2029use U-2948
11850182September 2029product
11628088February 2027product

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SKYLA patent cliff — loss of exclusivity September 2029 | CliffBio